News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
679,835 Results
Type
Article (60833)
Company Profile (204)
Press Release (618797)
Multimedia
Podcasts (115)
Webinars (16)
Section
Business (182176)
Career Advice (3087)
Deals (33016)
Drug Delivery (128)
Drug Development (83724)
Employer Resources (173)
FDA (16990)
Job Trends (15015)
News (326179)
Policy (35361)
Tag
Academia (2895)
Academic (2)
Accelerated approval (11)
Adcomms (31)
Allergies (101)
Alliances (47418)
ALS (117)
Alzheimer's disease (1531)
Antibody-drug conjugate (ADC) (187)
Approvals (16951)
Artificial intelligence (348)
Autoimmune disease (33)
Automation (12)
Bankruptcy (309)
Best Places to Work (11824)
BIOSECURE Act (20)
Biosimilars (133)
Biotechnology (149)
Bladder cancer (97)
Brain cancer (40)
Breast cancer (384)
Cancer (3012)
Cardiovascular disease (237)
Career advice (2605)
Career pathing (34)
CAR-T (199)
CDC (37)
Cell therapy (517)
Cervical cancer (24)
Clinical research (68523)
Collaboration (1061)
Company closure (3)
Compensation (593)
Complete response letters (31)
COVID-19 (2850)
CRISPR (64)
C-suite (311)
Cystic fibrosis (117)
Data (3009)
Decentralized trials (2)
Denatured (29)
Depression (74)
Diabetes (371)
Diagnostics (6441)
Digital health (21)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (164)
Drug pricing (152)
Drug shortages (36)
Duchenne muscular dystrophy (126)
Earnings (73284)
Editorial (47)
Employer branding (22)
Employer resources (154)
Events (103062)
Executive appointments (798)
FDA (18694)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (924)
Gene editing (136)
Generative AI (33)
Gene therapy (405)
GLP-1 (910)
Government (5089)
Grass and pollen (5)
Guidances (175)
Healthcare (19421)
HIV (44)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (174)
Immuno-oncology (10)
Indications (40)
Infectious disease (3038)
Inflammatory bowel disease (153)
Inflation Reduction Act (13)
Influenza (66)
Intellectual property (121)
Interviews (556)
IPO (16205)
IRA (55)
Job creations (3593)
Job search strategy (2154)
Kidney cancer (14)
Labor market (43)
Layoffs (540)
Leadership (26)
Legal (7891)
Liver cancer (85)
Longevity (12)
Lung cancer (422)
Lymphoma (213)
Machine learning (11)
Management (61)
Manufacturing (406)
MASH (96)
Medical device (13170)
Medtech (13175)
Mergers & acquisitions (17544)
Metabolic disorders (942)
Multiple sclerosis (102)
NASH (23)
Neurodegenerative disease (135)
Neuropsychiatric disorders (40)
Neuroscience (2259)
NextGen: Class of 2025 (6823)
Non-profit (4886)
Now hiring (30)
Obesity (487)
Opinion (286)
Ovarian cancer (103)
Pain (117)
Pancreatic cancer (122)
Parkinson's disease (194)
Partnered (21)
Patents (302)
Patient recruitment (164)
Peanut (53)
People (51892)
Pharmaceutical (43)
Pharmacy benefit managers (25)
Phase I (21107)
Phase II (29907)
Phase III (22733)
Pipeline (1639)
Policy (233)
Postmarket research (3040)
Preclinical (9129)
Press Release (62)
Prostate cancer (145)
Psychedelics (44)
Radiopharmaceuticals (276)
Rare diseases (505)
Real estate (5514)
Recruiting (72)
Regulatory (25063)
Reports (39)
Research institute (2587)
Resumes & cover letters (519)
Rett syndrome (10)
RNA editing (9)
RSV (54)
Schizophrenia (95)
Series A (155)
Series B (108)
Service/supplier (8)
Sickle cell disease (66)
Special edition (22)
Spinal muscular atrophy (163)
Sponsored (34)
Startups (3440)
State (2)
Stomach cancer (16)
Supply chain (78)
Tariffs (63)
The Weekly (84)
Vaccines (865)
Venture capital (54)
Weight loss (324)
Women's health (48)
Worklife (20)
Date
Today (68)
Last 7 days (373)
Last 30 days (1910)
Last 365 days (31037)
2025 (16747)
2024 (35241)
2023 (40402)
2022 (51256)
2021 (55740)
2020 (54426)
2019 (48119)
2018 (36492)
2017 (32575)
2016 (31684)
2015 (36187)
2014 (28515)
2013 (24165)
2012 (25888)
2011 (26491)
2010 (24468)
Location
Africa (973)
Alabama (68)
Alaska (6)
Arizona (199)
Arkansas (13)
Asia (41768)
Australia (7043)
California (7107)
Canada (2315)
China (701)
Colorado (311)
Connecticut (318)
Delaware (198)
Europe (93068)
Florida (1108)
Georgia (239)
Hawaii (1)
Idaho (56)
Illinois (647)
India (30)
Indiana (323)
Iowa (14)
Japan (232)
Kansas (106)
Kentucky (30)
Louisiana (11)
Maine (62)
Maryland (1028)
Massachusetts (5368)
Michigan (207)
Minnesota (428)
Mississippi (3)
Missouri (87)
Montana (26)
Nebraska (25)
Nevada (72)
New Hampshire (65)
New Jersey (2030)
New Mexico (30)
New York (2057)
North Carolina (1090)
North Dakota (8)
Northern California (3130)
Ohio (226)
Oklahoma (16)
Oregon (35)
Pennsylvania (1501)
Puerto Rico (14)
Rhode Island (33)
South America (1270)
South Carolina (34)
South Dakota (1)
Southern California (2688)
Tennessee (123)
Texas (1074)
United States (26691)
Utah (204)
Virginia (191)
Washington D.C. (72)
Washington State (603)
West Virginia (4)
Wisconsin (70)
679,835 Results for "national institute on drug abuse nida".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
June 4, 2025
·
4 min read
Pharm Country
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.
March 14, 2024
·
3 min read
Press Releases
DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain
June 25, 2025
·
4 min read
Bio NC
Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody
Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).
October 18, 2023
·
4 min read
Drug Development
STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).
March 8, 2023
·
3 min read
Biotech Bay
MAPS PBC Announces National Institute on Drug Abuse to Share Data for New Drug Application for MDMA-Assisted Therapy for Treatment of PTSD
MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).
June 21, 2023
·
5 min read
Genetown
Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders
Delix Therapeutics today announced it has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support the advancement of DLX-007.
December 13, 2023
·
5 min read
Press Releases
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
March 13, 2025
·
6 min read
Pharm Country
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).
November 6, 2023
·
11 min read
Drug pricing
Low-Price Drug Nations Catching ‘Free Ride’ on US Innovation, Report Says
No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative medicines by 90% and mislead U.S. policymakers into thinking Americans are overpaying.
May 2, 2025
·
3 min read
·
Annalee Armstrong
1 of 67,984
Next